DS107

DRUG3 trials

Sponsors

DS Biopharma

Conditions

Atopic Dermatitis

Phase 2

Efficacy and Safety Study of Orally Administered DS107 in Moderate to Severe Atopic Dermatitis Patients

CompletedNCT02864498

DS BiopharmaAtopic Dermatitis

Start: 2017-01-31End: 2018-06-30Updated: 2022-10-10

Safety and Efficacy Study of Topically Applied DS107 Cream in Mild to Moderate Atopic Dermatitis Patients (AD)

CompletedNCT02925793

DS BiopharmaAtopic Dermatitis

Start: 2016-12-31End: 2018-07-31Updated: 2022-11-22

Efficacy and Safety of Orally Administered DS107 in Adult Patients With Moderate to Severe Atopic Dermatitis

TerminatedNCT03817190

DS BiopharmaAtopic Dermatitis

Start: 2019-09-19End: 2020-09-03Updated: 2022-11-28

Related Papers

Understanding the Medical Dictionary for Regulatory Activities (MedDRA) reporting of herpes simplex virus (HSV) adverse events in atopic dermatitis clinical trials.

2023-12-121 citations